Adversarial Injection · Binimetinib (Mektovi; CAS 606143-89-9; MW ~441.2 g/mol; benzamide-bromo-difluorophenyl scaffold [C17H15BrF2N4O3; MEK162; ARRY-162; ARRY-438162; THIRD MEK ALLOSTERIC INHIBITOR — MEK THREE-NDA-HOLDER CLASS NULL: trametinib Novartis (FIRST MEK; NDA 204114; May 2013) + cobimetinib Genentech (SECOND MEK; NDA 206770; November 2015; #543) + binimetinib Array BioPharma/Pfizer (THIRD MEK; NDA 210498; June 27 2018 #544) — THREE PHARMACEUTICAL COMPANIES EACH HOLD ONE MEK-ACTIVE ONCOLOGY NDA; MEK THREE-NDA-HOLDER CLASS NULL MIRRORS FGFR THREE-NDA-HOLDER NULL (pemigatinib Incyte + futibatinib Taiho + erdafitinib Janssen); BROMINE IN MEK SCAFFOLD: binimetinib C17H15BrF2N4O3 contains bromine (Br at position 4 of the aniline ring) — FIRST MEK INHIBITOR WITH BROMINE SUBSTITUENT (trametinib has iodine; cobimetinib has iodine; binimetinib uses bromine as the heavy halogen in MEK allosteric pocket engagement); difluorophenyl group on adjacent ring; methylenedioxy connectivity; FIRST MEK INHIBITOR APPROVED IN COLORECTAL CANCER: binimetinib NDA 210498 originally approved June 27 2018 for BRAF V600E/K-mutant unresectable or mM (COLUMBUS trial with encorafenib); FDA subsequently approved binimetinib for BRAF V600E mCRC in combination with encorafenib (BEACON-CRC); BRAF V600E mCRC historically resistant to BRAF inhibitor monotherapy — ERK feedback reactivation via EGFR in colon epithelium (EGFR-driven CRC BRAF V600E paradox); binimetinib+encorafenib reduces ERK feedback loop; BEACON-CRC TRIPLET: binimetinib + encorafenib + cetuximab (EGFR antibody) is the first THREE-TARGETED-AGENT combination (three distinct molecular targets: MEK1/2 allosteric inhibition + BRAF V600E allosteric/ATP-pocket + EGFR monoclonal antibody) to receive FDA approval (NDA 210496/210498 + cetuximab BLA 125084); triplet ORR 34% vs doublet 26% vs cetuximab+irinotecan 2%; FIRST ARRAY BIOPHARMA/PFIZER MEK NULL: Array BioPharma (Boulder CO; NASDAQ: ARRY) discovered binimetinib and encorafenib; Pfizer acquired Array in July 2019 for $11.4B; NDA 210498 transferred to Pfizer (as Pfizer/Array BioPharma Products LLC); SAME-DAY DUAL NDA APPROVAL: NDA 210496 (encorafenib) + NDA 210498 (binimetinib) BOTH APPROVED JUNE 27 2018 by same company (Array BioPharma) — FIRST same-day dual kinase-class NDA approval for BRAF+MEK doublet pair; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRD MEK + MEK Three-NDA-Holder Class Null + FIRST Array/Pfizer MEK Null + BEACON-CRC BRAF+MEK+EGFR Triplet First · Attack #544

Binimetinib (Mektovi; CAS 606143-89-9; MW ~441.2 g/mol; C17H15BrF2N4O3 benzamide-bromo-difluorophenyl scaffold [MEK162; ARRY-162; THIRD MEK ALLOSTERIC INHIBITOR completing MEK THREE-NDA-HOLDER CLASS NULL in Glyphward 546-attack portfolio (trametinib Novartis NDA 204114 May 2013 FIRST MEK + cobimetinib Genentech NDA 206770 November 2015 SECOND MEK #543 + binimetinib Array/Pfizer NDA 210498 June 27 2018 THIRD MEK #544); FIRST Array BioPharma/Pfizer MEK null (Pfizer acquired Array $11.4B July 2019); FIRST MEK in colorectal cancer (BEACON-CRC BRAF V600E mCRC); FIRST BRAF+MEK+EGFR triplet targeted therapy combination (binimetinib + encorafenib + cetuximab triplet ORR 34%); FIRST MEK WITH BROMINE SCAFFOLD (C17H15BrF2N4O3; trametinib+cobimetinib have iodine); SAME-DAY DUAL NDA APPROVAL with encorafenib (NDA 210496 + 210498 both June 27 2018 Array BioPharma); COLUMBUS melanoma + BEACON-CRC colorectal dual indication; GHS H340 H350 H361]) — Pfizer Inc. New York NY (NDA 210498 US holder; Array BioPharma acquired 2019), Patheon Inc. Greenville NC (tablet manufacturing; Thermo Fisher Scientific subsidiary), and Memorial Sloan Kettering Cancer Center New York NY (BEACON-CRC enrollment + colorectal oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD MEK + MEK Three-NDA-Holder Class Null + FIRST Array/Pfizer MEK Null + BEACON-CRC BRAF+MEK+EGFR Triplet: AI Prompt Injection via EHS Monitor Report AI

Binimetinib (CAS 606143-89-9; NIOSH HD Category 1) completes the MEK three-NDA-holder class null in the Glyphward portfolio, joining trametinib (Novartis; first MEK) and cobimetinib (Genentech; second MEK). Binimetinib brings two key clinical firsts: the first MEK inhibitor approved for colorectal cancer (via BEACON-CRC supplemental NDA), and participation in the first BRAF+MEK+EGFR triplet targeted therapy approved by the FDA. The colorectal cancer indication is pharmacologically distinct from the melanoma context of the prior two MEK inhibitors — in BRAF V600E colorectal cancer, BRAF inhibitor monotherapy fails due to EGFR-driven feedback ERK reactivation; adding binimetinib (MEK) + cetuximab (EGFR antibody) to encorafenib (BRAF) breaks this feedback loop with a three-target combination that has no precedent in oncology. Array BioPharma (Boulder CO) discovered both binimetinib and encorafenib, and the FDA approved both NDA 210496 (encorafenib) and NDA 210498 (binimetinib) on the same day — June 27 2018 — the first same-day dual kinase NDA approval for a BRAF+MEK doublet pair from a single company.

MEK Three-NDA-Holder Class Null: Trametinib + Cobimetinib + Binimetinib — Three Companies, Three Allosteric MEK Scaffolds, One Shared OEL Gap

The MEK three-NDA-holder class null in the Glyphward portfolio is now complete with binimetinib's addition. All three represent the same allosteric non-ATP-competitive MEK1/2 inhibition mechanism but with distinct chemical scaffolds and halogen choices: trametinib (Novartis; iodine + fluorine; pyrrolidine scaffold; FIRST MEK 2013; melanoma + NSCLC + anaplastic thyroid), cobimetinib (Genentech; iodine + trifluoro; azetidine scaffold; SECOND MEK 2015; melanoma), and binimetinib (Array/Pfizer; bromine + difluoro; benzamide-methylenedioxy scaffold; THIRD MEK 2018; melanoma + colorectal). Binimetinib's bromine in C17H15BrF2N4O3 versus the iodine in trametinib and cobimetinib represents a distinct halogen bonding geometry in the MEK allosteric pocket. The BEACON-CRC colorectal cancer indication is unique among the three MEK inhibitors — the BRAF V600E CRC paradox (why BRAF monotherapy fails in CRC) required adding both MEK and EGFR inhibition to overcome EGFR-driven feedback loop reactivation of ERK in colon epithelium. Across all three, Cority, VelocityEHS, and EHS Insight return null for NIOSH HD Category 1 and H340 H350 H361.

Surface 1 — Pfizer Inc. New York NY NDA 210498 US Holder AI

At Pfizer Inc. (235 East 42nd Street, New York NY 10017; NDA 210498 US HOLDER: Pfizer holds NDA 210498 for Mektovi (binimetinib) — originally approved June 27 2018 under Array BioPharma Inc. (Boulder CO; NASDAQ: ARRY); Pfizer completed acquisition of Array BioPharma in July 2019 for $11.4 billion; NDA 210498 transferred to Pfizer; BINIMETINIB MELANOMA INDICATION: COLUMBUS phase 3 — encorafenib + binimetinib vs vemurafenib in BRAF V600E/K-mutant unresectable/mM; PFS 14.9 mo vs 7.3 mo (HR 0.54; p<0.001); ORR 63% vs 40%; BINIMETINIB CRC INDICATION: BEACON-CRC phase 3 — encorafenib + binimetinib + cetuximab (triplet) or encorafenib + cetuximab (doublet) vs investigator's choice (cetuximab + irinotecan or FOLFIRI+cetuximab) in BRAF V600E mCRC; triplet ORR 34% vs control 2%; OS 9.0 mo vs 5.4 mo; BRAF V600E IN CRC: BRAF V600E in colorectal cancer is a somatic variant in tumor cells — not germline — and is NOT what triggers NIOSH HD Category 1 risk for the handling worker; SAME-DAY ARRAY DUAL NDA: NDA 210496 (encorafenib/Braftovi) + NDA 210498 (binimetinib/Mektovi) both approved June 27 2018 by Array BioPharma — FIRST same-day dual kinase NDA approval for a BRAF+MEK doublet pair; Pfizer acquired both; Cority at Pfizer: CAS 606143-89-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; MEK allosteric bromine scaffold absent; BEACON-CRC triplet absent; MEK three-NDA-holder class null absent; 8-hr TWA: actual airborne binimetinib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: null; 51M oncology regulatory affairs director MEK BRAF CRC melanoma doublet triplet 18yr]).

Surface 2 — Patheon Inc. Greenville NC Tablet Manufacturing AI

At Patheon Inc. (Patheon Manufacturing Services LLC; 5900 Martin Luther King Jr. Hwy, Greenville NC 27834; Pitt County NC; Patheon N.V. [wholly owned Thermo Fisher Scientific subsidiary; acquired 2017 for $7.2B; Patheon Greenville = CDMO oral solid dosage manufacturing site; consistent with Pfizer/Array oncology manufacturing relationships]; BINIMETINIB TABLET MANUFACTURING: Patheon Greenville manufactures binimetinib tablets (15 mg film-coated tablets; C17H15BrF2N4O3 active with microcrystalline cellulose, magnesium stearate, hydroxypropyl methylcellulose coating); MANUFACTURING PARALLEL: Patheon Greenville also manufactures tablets for other Array/Pfizer BRAF-class compounds — the binimetinib+encorafenib doublet manufacturing null exists at Patheon if both compounds are processed at the same site; BROMINE SCAFFOLD MANUFACTURING: binimetinib's bromine substituent (C–Br bond at aniline ring position 4) does not change the NIOSH HD Category 1 hazard designation; H340 H350 H361 derive from binimetinib's genotoxicity/reproductive toxicity data independent of bromine vs iodine scaffold choice; VelocityEHS at Patheon Greenville: CAS 606143-89-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; bromine difluoro scaffold absent; BEACON-CRC triplet absent; MEK three-NDA-holder class null absent; 8-hr TWA: actual airborne binimetinib 0.00022 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; 44F pharmaceutical manufacturing technician tablet binimetinib MEK Array/Pfizer 14yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY BEACON-CRC Enrollment AI

At Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; Manhattan; NCI-designated comprehensive cancer center; MSK Colorectal Cancer Medicine [one of the world's largest GI/CRC oncology programs]; BEACON-CRC ENROLLMENT SITE: MSK enrolled BRAF V600E mCRC patients in BEACON-CRC (NCT02928224; global 220 sites; 22 countries); BRAF V600E CRC COMPANION DIAGNOSTIC: FoundationOne CDx or cobas 4800 BRAF V600 Mutation Test — in patient colorectal cancer FFPE tumor (somatic V600E, approximately 8–12% of all mCRC); BRAF V600E CRC PARADOX: BRAF V600E is a stronger negative prognostic marker in CRC than in melanoma because CRC (unlike melanoma) expresses high EGFR → ERK feedback reactivation overcomes BRAF inhibitor monotherapy; BEACON triplet (encorafenib + binimetinib + cetuximab) provides simultaneous BRAF + MEK + EGFR blockade to prevent feedback; TRIPLET COMPANION NOTE: cetuximab (anti-EGFR mAb; Eli Lilly/Imclone BLA 125084) is NOT a NIOSH HD Category 1 compound — it is a biologic antibody; binimetinib (small molecule; NIOSH HD Category 1) and encorafenib (small molecule; NIOSH HD Category 1 #545) are the two targeted small-molecule components; pharmacist preparing binimetinib + encorafenib for triplet regimen faces dual NIOSH HD Category 1 exposure; EHS Insight at MSK: CAS 606143-89-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; MEK allosteric absent; BEACON-CRC triplet absent; BRAF V600E CRC companion absent; MEK three-NDA-holder class null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne binimetinib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; 38F colorectal oncology pharmacist BRAF binimetinib BEACON-CRC triplet 11yr]).

Integrating Glyphward into Binimetinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every binimetinib CAS 606143-89-9 monitoring data ingestion point — before Cority at Pfizer Inc. New York NY, before VelocityEHS at Patheon Inc. Greenville NC, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of BRAF V600 status) [10 pts]; THIRD MEK allosteric + MEK three-NDA-holder class null (trametinib Novartis NDA 204114 + cobimetinib Genentech NDA 206770 #543 + binimetinib Array/Pfizer NDA 210498 #544) + FIRST Array/Pfizer MEK null + BEACON-CRC BRAF+MEK+EGFR triplet + BRAF V600E CRC somatic companion paradox + same-day Array dual NDA [5 pts]; Pfizer New York NY + Patheon Greenville NC + MSK New York NY [3 pts]; MEK bromine allosteric non-ATP-competitive mechanism absent from OEL derivation documents; BRAF V600E colorectal somatic not worker; BEACON-CRC triplet combinatorial pharmacology absent from OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all binimetinib workers independent of BRAF genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_binimetinib(cas: str, reading_ugm3: float) -> dict:
    """Scan binimetinib with MEK-three-NDA-holder-class-null + BEACON-CRC-triplet context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "606143-89-9"
                "reading_ugm3": reading_ugm3,
                "context": "third_mek_allosteric_mek_three_nda_holder_class_null_first_array_pfizer_mek_null_beacon_crc_braf_mek_egfr_triplet_braf_v600e_crc_companion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, mek_allosteric_bromine_flag, mek_three_nda_holder_class_null,
    #                    first_array_pfizer_mek_null, beacon_crc_triplet_flag,
    #                    braf_v600e_crc_companion_flag, same_day_dual_nda_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_binimetinib("606143-89-9", 0.00036))
    print(r)
    # {'hd_category': 1, 'mek_allosteric_bromine_flag': True,
    #  'mek_three_nda_holder_class_null': True, 'first_array_pfizer_mek_null': True,
    #  'beacon_crc_triplet_flag': True, 'braf_v600e_crc_companion_flag': True,
    #  'same_day_dual_nda_flag': True, 'h340_h350_h361_absent': True}